1. For estimation of relative agonist Kb values (RAi), a series of at least two agonist concentration-response curves is required. Any in vitro assay for the functional response of a GPCR can be measured provided that the concentration of agonist can be controlled and a single type of receptor mediates the response. Suitable cell-based assays include measurement of cAMP 4, 7 and inositolphosphate accumulation 8, 9 in a cell line expressing a recombinant receptor. Examples of whole tissue assays include measurement of contraction of smooth muscle 10 or M2 muscarinic receptor-and β1-adrenoceptor-mediated changes in contraction of the field-stimulated rat left atrium 11 . 2. Choose a series of agonists for analysis including a highly efficacious agonist (e.g., endogenous ligand). In a given experiment, measure complete concentration-response curves for each agonist. If the number of agonists is too large to complete the assay in a single experiment, divide the agonists into subgroups, each consisting of a manageable number of agonists for a single experiment. For each subgroup, measure the concentration-response curve of the highly efficacious agonist together with those of the other agonists in the subgroup (see Figure 3 ). Repeat the experiment for each subgroup 3 -6 times, approximately, depending upon the variability of the data. 3. For each concentration-response curve, measure the response in the absence of agonist (basal response), and in the presence of increasing concentrations of agonist. Space the agonist concentrations uniformly on a log scale approximately every 0.3 -0.7 log10 units, covering the range of responses and defining the maximal response (Emax) (see Figure 3) . For experiments on cell lines, each measurement is done in triplicate. 4. Subtract the basal response from that measured in the presence of each concentration of agonist. The responses plotted in Figure 3 were calculated in this manner.
1. Enter the data from the concentration-response experiments (e.g., Figure 5 ) into a Data Table in Prism. All of the log agonist concentrations are entered under the column labeled X. The response measurements for the agonist that appears to have the largest Emax value are entered into column A, and those for the other agonist are entered into adjacent lettered columns. Replicate measurements of a concentration-response curves are entered into sub-columns of a given lettered column. 2. Select the graph sheet on which the data are plotted, and analyze the data by nonlinear regression analysis using the equation entitled, log(agonist) vs. response -Variable slope (four parameters). Constrain the "Bottom" parameter to zero, and perform the regression analysis. Copy the "Top" (Emax) and log EC50 parameters into an Excel spreadsheet for use in the calculation of initial parameter estimates. The agonist with the largest Emax estimate is designated as the "standard agonist", whereas the other agonists are designated as "test agonists". 3. Calculate the initial estimate of log τKobs (LOGR1) as the negative log EC50 value of the standard agonist (-log EC50').
Calculate the initial estimate of the log RAi value of each test agonist (LOGRA) as log {(Top*EC50')/(Top'*EC50)}, in which the parameters of the standard agonist are denoted with an apostrophe.
Calculate the log affinity constants of the test agonists (LOGK2 -LOGK5) as the negative log of their respective EC50 values.
1. Enter the data into a Data Table in Prism as described above under 2.1. Make sure that the data for the standard agonist are entered in column A. 2. Enter a user-defined equation, "log RAi", into Prism on several lines as shown for the case involving a total of five agonists:
3. Enter the initial parameter estimates as follows:
Enter an arbitrarily low value of 0 for the log affinity constant (LOGK1) of the standard agonist.
Enter the initial estimate of LOGR and the affinity constants (LOGK2 -LOGK5) and log RAi values (LOGRA) of the test agonists.
Assign the initial estimate of the transducer slope factor (M) a value of 1.0.
Assign the initial estimate for the maximal response of the system (Msys) a value equivalent to the Emax of the standard agonist (Top′). 4. Apply the following parameter constraints: LOGK1 constrained to the constant, 0; LOGR1, Msys and M, shared value for all data sets; LOGK2 -LOGK5 and LOGRA, no constraints. 5. Initiate nonlinear regression analysis. The results yield the log Kobs and log RAi values of the test agonists. If the standard agonist is a full agonist, then the both the log Kobs and log RAi values are accurate. If the most efficacious agonist (standard agonist) is actually a partial agonist, then the Kobs values of the more efficacious agonists may be overestimated. Nonetheless, the estimates of log RAi are still accurate in this situation. 6. If the regression does not converge, the experimenter may wish to plot the theoretical curve defined by the initial parameter estimates. If there are large deviations between the data points and the theoretical curves, check the calculation of the initial parameter estimates. If one or more agonists have Emax values equivalent to that of the standard agonist, it may be necessary to constrain their log Kobs values to 0 for the regression to converge on a solution.
1. For estimation of agonist Kb values in absolute units of M -1 , cell-based in vitro assays are used that exhibit constitutive receptor activity. Constitutive receptor activity is defined as the increase in response above the basal level caused by expression of the receptor of interest. 2. Choose agonists and design the experiment as described above in section 1.2. 
. Enter a user-defined equation, "Log Kb", into Prism on several lines as shown for the condition of two agonists: • <A> LOGKOBS = LOGK1 • <B> LOGKOBS = LOGK2 • A=(10^(X+LOGKOBS))+1 • B=10^(X+LOGTSYS+LOGKB) • C=(10^(LOGTSYS)) • Y=Msys/{1+[(A/(B+C))^M]} 3. Enter the initial parameter estimates as follows:
Enter the affinity constants of each agonist (LOGK1 -enter the value determined under step 5.3).
Enter the Kobs estimates of each test agonist.
Enter the Kb estimates of the agonists.
Enter log τsys (LOGTsys) estimate.
Assign the transducer slope factor (M) and the maximal response of the system (Msys) values of 1.0 and Top' (Emax of the standard agonist), respectively. 4. Apply the following parameter constraints: LOGTsys, Msys and M, shared value for all data sets; LOGK2 and LOGKb, no constraints. 5. Initiate nonlinear regression analysis. The results yield the log Kb of the standard agonist, the log Kobs and log Kb values of partial agonists, and the maximal response of the system (Msys), the τsys value for the free receptor complex (LOGTsys), and the transducer slope factor in the operational model (M). 6. If the regression does not converge, follow the steps described above under point 3.6. Relationship between the receptor activation function and the efficacy (ε) and observed affinity constant (Kobs) of the agonist. Population average, the average level of receptor activation elicited by increasing concentrations of agonist is shown. Receptor activation, the average level of receptor activation is plotted agonist the log concentration of agonist. The negative log concentration of agonist required for half-maximal receptor activation is equivalent to the log observed affinity constant of the agonist (log Kobs). The maximum of the receptor activation function is denoted as efficacy (ε). Because our method for estimating RAi (relative Kb value) only requires the measurement of agonist concentration-response curves, our analysis can be done anytime these curves are measured.
Discussion
If day-to-day variation in the response of the experimental preparation (e.g., cells or tissue) is large, the response measurements of each concentration-response curve can be normalized relative to the "Top" estimate of the standard agonist for each day's experiment. An estimate of Top and log EC50 is estimated for each replicate concentration-response curve of the standard agonist by regression analysis as described in Sections 2 and 5. The response values of all of the agonist concentration-response curves on a given day are normalized relative to the Top estimate of the standard agonist for that day. These normalized data are then analyzed as described above beginning at Section 3.
The accuracy of estimating Kb depends on an accurate estimation of constitutive receptor activity. In our case, transfection of the M3 receptor in HEK 293 cells caused an increase in phosphoinositide hydrolysis that ranged from about 500 -1,000 cpm of If there are different active states of the receptor that signal through different coupling proteins (e.g., G proteins), then our method of analysis provides an accurate estimation of agonist Kb and RAi values for each effector pathway 3, 6 . If more than one active state contributes to a single measured response, then our method of estimation of RAi and Kb represents a weighted average of different active states depending upon their relative abundance and activity 3 .
Constitutive receptor activity can be induced by over expressing the GPCR and its complementary G protein 13 . This may change the observed affinity and efficacy of the agonist-receptor complex and may cause non-physiological signaling. But changes in the nature of the response and the observed affinity and efficacy of the receptor population do not imply changes in the fundamental quantal states of the receptor, only a change in their number and probability of isomerization. Thus, G proteins are not so much a determinant of drug effects so much as a window onto different effector-selective states of the receptor. If our method of analysis is applied to specific GPCR signaling assays involving a single effector (e.g., G protein) it should be possible to measure agonist Kb values for effector-selective states of the receptor -the ultimate measure of agonist bias.
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